Patient perception of treatment efficacy, disability and health satisfaction by Attipoe, L & Ciurtin, C
BSR Abstract 2016 
 
Category: Health Services Research, Economics and Outcomes  
 
Title 
Patient perception of treatment efficacy, disability and health satisfaction 
 
L. Attipoe 1,*, C. Ciurtin 1 
1Rheumatology, University College London, United Kingdom 
 
Background 
Patient satisfaction encompasses experiences of care and treatment outcomes such as efficacy, 
health state and disability. Addressing these factors should improve satisfaction and patient 
outcomes. 
 
Methods 
115 questionnaires were randomly distributed to patients with inflammatory arthritis attending 
rheumatology clinics at University College Hospital, London between November 2014 and January 
2015. Response rate was 90%. Questions were semi-structured, using Likert/visual analogue scales, 
and focused on diagnosis, symptomatology, treatment history, health status and clinic attendance 
experience. 
 
Results 
Rheumatoid arthritis represented 69% of inflammatory arthritis patients, 64% were female. Mean age 
in years was 50.44±17.98. 5.94% of patients had disease duration < 1 year and 57% of patients had a 
duration > 10 years. Current treatment regime showed 23% to be on DMARDs alone, 33% on 
biologics alone and 44% on combination therapy. Mean number of drugs before current drug regime 
was 3.06±2.13. 72% of respondents assessed their current treatment regime as effective (Mean HAQ 
1.28±0.82, Mean GVAS 39.44±29.44). Only 17% of this perceived effective treatment group had a 
HAQ score < 0.5 and 44% had a GVAS < 30. 68.6% of respondents identified themselves as having a 
disability (Mean HAQ 1.52 ±0.73, Mean GVAS 45.87 ±29.81). 80% of those with a perceived disability 
had a HAQ score > 1. Significant differences were found between patient groups as shown in Table 1. 
 
Conclusion 
Health satisfaction is significantly linked to perceived treatment efficacy but not perceived disability 
levels. High perception of disability and low perception of treatment efficacy are significantly 
associated with factors less commonly discussed in consultations such as fatigue and involvement in 
decision making. Interestingly, those who had low perceived efficacy levels were significantly less 
likely to view themselves as having a disability despite there not being a difference in HAQ scores 
between the two groups. This may reflect differing levels of acceptability regarding loss of function 
and the stigma that this brings. It is important to address the factors that influence patients’ 
satisfaction levels especially when making management decisions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Self-reported factors in association with perceived disability and treatment 
efficacy levels 
 
 
 
 Perceive 
self to 
have a 
disability 
(%) 
Perceive 
self NOT 
to have a 
disability 
(%) 
p value Current 
treatment 
effective 
(%) 
Current 
treatment 
NOT 
effective 
(%) 
p value 
Mean HAQ ±SD 1.52 
±0.73 
1.01  
±0.82 
0.004 1.28 
±0.82 
1.43 
±0.69 
0.578 
Mean GVAS ±SD 45.87 
±29.81 
43  
±30.48 
0.661 39.44 
±29.55 
57.17 
±27.51 
0.009 
Disease duration > 10 
years 
61.8 46.7 0.050 66.66 40 0.066 
Arthritis Health 
Satisfaction 
76.12 64.52 0.26 86.49 40 0.0001 
Presence of nocturnal 
joint pain 
47.8 28.1 0.283 33.3 60 0.039 
Sleep disturbance 60.9 37.5 0.079 45.3 68 0.164 
Morning stiffness > 
30mins 
39.1 53.1 0.510 36 75 0.00007 
Fatigue 68.1 43.8 0.033 53.3 72 0.515 
Low mood 18.8 12.5 0.019 10.7 28 0.116 
Interest in self 
management 
65.7 70 0.675 61.6 78.3 0.143 
Self identify with 
having a disability 
68.6 31.4  73.9 52 0.041 
Feel listened to 92.8 90.6 0.743 93.3 88 0.128 
Involved in decision 
making 
94.2 93.7 0.485 93.3 40 0.040 
Given emotional 
support 
74.6 80.7 0.820 80.6 72 0.452 
 
